Evidence map›Paper›PMID 42529093›Full record

ArticleFrontiers in pharmacology2026

VLX1570 suppresses neuroblastoma growth through inhibition of PCNA-associated proliferative signaling and potentiates cisplatin antitumor activity.

Wei-Hsun Yang, Chong-Sun Khoi, Kuan-Lin Kuo, Po-Ming Chow, Chen-Hsun Hsu, Yi-Ju Kao, Wei-Chou Lin, Shang-Jen Chang, Shih-Ming Liao, Felicia Tai and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Wei-Hsun YangGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chong-Sun KhoiDepartment of Anesthesiology, Far-Eastern Memorial Hospital, New Taipei City, Taiwan.
Kuan-Lin KuoDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Po-Ming ChowDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chen-Hsun HsuDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Yi-Ju KaoDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Wei-Chou LinDepartment of Pathology, College of Medicine, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.
Shang-Jen ChangDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shih-Ming LiaoDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Felicia TaiTaipei European School, Taipei, Taiwan.
Chung-Sheng ShiGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Shing-Hwa LiuGraduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Pey-Jium ChangGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Chung-Cheng WangDepartment of Urology, En Chu Kong Hospital, College of Medicine, National Taiwan University, New Taipei City, Taiwan.
Kuo-How HuangDepartment of Urology, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite intensive multimodal therapy, high-risk neuroblastoma remains associated with poor clinical outcomes because of treatment resistance, recurrence, and progressive disease, underscoring the need for new therapeutic strategies. We investigated whether proteasome-associated deubiquitinating enzymes are therapeutically relevant in neuroblastoma by assessing ubiquitin C-terminal hydrolase L5 (UCHL5) and ubiquitin-specific protease 14 (USP14) expression in neuroblastoma tissues and evaluating the antitumor activity of VLX1570 in preclinical models. Immunohistochemical (IHC) analysis showed stronger UCHL5 and USP14 immunoreactivity in neuroblastoma tissues than in normal peripheral nerve tissue. In human neuroblastoma cell lines IMR-32, SK-N-SH, and SH-SY5Y, VLX1570 reduced cell viability in a dose- and time-dependent manner, induced apoptosis, and triggered G2/M arrest. These effects were accompanied by induction of CCAAT/enhancer-binding protein homologous protein (CHOP) and suppression of proliferating cell nuclear antigen (PCNA)-associated proliferative signaling, as reflected by reduced expression of PCNA, phospho-histone H3, and Bcl-2 together with increased p21 and p53 expression. PCNA knockdown experiments further supported inhibition of PCNA-associated proliferative signaling as a functionally relevant component of VLX1570-induced cytotoxicity. In addition, VLX1570 enhanced cisplatin-induced apoptosis

Indexed as

apoptosiscisplatinneuroblastomaPCNAproteasome-associated deubiquitinating enzymesVLX1570

Identifiers

PMID42529093
PMCPMC13416542

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.